JP2018502077A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502077A5
JP2018502077A5 JP2017532649A JP2017532649A JP2018502077A5 JP 2018502077 A5 JP2018502077 A5 JP 2018502077A5 JP 2017532649 A JP2017532649 A JP 2017532649A JP 2017532649 A JP2017532649 A JP 2017532649A JP 2018502077 A5 JP2018502077 A5 JP 2018502077A5
Authority
JP
Japan
Prior art keywords
compound
formula
ibrutinib
phenoxyphenyl
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502077A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/013424 external-priority patent/WO2016115356A1/en
Publication of JP2018502077A publication Critical patent/JP2018502077A/ja
Publication of JP2018502077A5 publication Critical patent/JP2018502077A5/ja
Pending legal-status Critical Current

Links

JP2017532649A 2015-01-14 2016-01-14 ブルトンチロシンキナーゼ阻害剤の合成 Pending JP2018502077A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14
US62/103,507 2015-01-14
PCT/US2016/013424 WO2016115356A1 (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020171454A Division JP2021035947A (ja) 2015-01-14 2020-10-09 ブルトンチロシンキナーゼ阻害剤の合成

Publications (2)

Publication Number Publication Date
JP2018502077A JP2018502077A (ja) 2018-01-25
JP2018502077A5 true JP2018502077A5 (enExample) 2019-02-28

Family

ID=56406389

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017532649A Pending JP2018502077A (ja) 2015-01-14 2016-01-14 ブルトンチロシンキナーゼ阻害剤の合成
JP2020171454A Pending JP2021035947A (ja) 2015-01-14 2020-10-09 ブルトンチロシンキナーゼ阻害剤の合成

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020171454A Pending JP2021035947A (ja) 2015-01-14 2020-10-09 ブルトンチロシンキナーゼ阻害剤の合成

Country Status (16)

Country Link
US (6) US20180009814A1 (enExample)
EP (1) EP3245208A4 (enExample)
JP (2) JP2018502077A (enExample)
KR (1) KR20170102887A (enExample)
CN (2) CN107108640A (enExample)
AU (2) AU2016206693A1 (enExample)
BR (1) BR112017015206B1 (enExample)
CA (2) CA2971460C (enExample)
HK (1) HK1246293A1 (enExample)
IL (4) IL322449A (enExample)
MA (1) MA41350A (enExample)
MX (2) MX366827B (enExample)
RU (1) RU2017128308A (enExample)
SG (2) SG11201705678YA (enExample)
WO (1) WO2016115356A1 (enExample)
ZA (1) ZA201704338B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2712440C2 (ru) * 2015-02-12 2020-01-29 Шанхай Дьюд Медикал Сайенс Энд Текнолоджи Ко., Лтд Способ получения ибрутиниба
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
CN110944999A (zh) 2017-08-01 2020-03-31 勃林格殷格翰国际有限公司 中间体化合物和方法
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
JP6944496B2 (ja) 2018-10-22 2021-10-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
AU2018448845B2 (en) 2018-11-09 2022-03-24 Taiho Pharmaceutical Co., Ltd. Method for producing dimethoxybenzene compound
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
KR20220011669A (ko) 2019-05-21 2022-01-28 얀센 파마슈티카 엔.브이. Btk 억제제 제조를 위한 방법 및 중간체
JP7658916B2 (ja) * 2019-05-21 2025-04-08 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を調製するためのプロセス及び中間体
US20240092785A1 (en) 2021-01-21 2024-03-21 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
EP2228369A1 (en) * 2003-12-23 2010-09-15 Astex Therapeutics Ltd. Pyrazole derivatives as protein kinase modulators
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2139487B1 (en) * 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CA2879400A1 (en) * 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
US10266535B2 (en) * 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof

Similar Documents

Publication Publication Date Title
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
MX2020003458A (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
MX2014001669A (es) Compuestos de fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-feni l]-2-alcoxi-2-alquinil/alquenil-etil}-1h-[1,2,4]triazol sustituidos.
JP2016130266A5 (enExample)
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
WO2008121634A3 (en) Nucleoside phosphoramidate prodrugs
MX2014001671A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-aluiniloxi-etil}-1h[1,2,4]triazol sustituidos.
EP4328223A3 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
SG10201804791UA (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
CL2014000202A1 (es) Compuestos fungicidas de 1-(2-(2-halo-4-(4-halogen-fenoxi)-fenil)-2-alcoxi-3-metil-butil)-1h(1,2,4)triazol sustituidos; proceso para preparar dicho compuesto; uso de dichos compuestos para combatir hongos fitopatogenos.
MX390748B (es) Composiciones y metodos para tratar accidente cerebrovascular isquemico.
WO2019132561A8 (ko) 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CU24671B1 (es) Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación
RU2017128308A (ru) Синтез ингибитора тирозинкиназы брутона
WO2010024930A3 (en) Cortistatin analogues and syntheses therof
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
PH12015501571A1 (en) Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline
JP2015057437A5 (enExample)
JP2017507175A5 (enExample)
CN110891950A (zh) 一种三嗪化合物及其药学上可接受的盐
WO2016038628A3 (en) A process for preparing olodaterol and intermediates thereof
MX2021011775A (es) Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
MY156955A (en) Antifungal agents
JP2018526320A5 (enExample)
WO2008008327A3 (en) Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound